Moody's alters Pfizer view to positive

Moody's Investors Service said it affirmed Pfizer Inc.’s A2 senior unsecured long-term ratings and revised the outlook to positive from stable.

The positive outlook reflects an expectation for greater financial flexibility because of ongoing high sales of Comirnaty, the Covid-19 vaccine. Additionally, Pfizer has opportunities to earn substantial revenue and profit from an experimental Covid antiviral pill under review by regulators, the agency said.

"While the longer-term magnitude of these products is difficult to quantify, rapid growth in cash levels provides Pfizer with opportunities for credit-enhancing acquisitions," stated Michael Levesque, a Moody's senior vice president, in a press release.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.